Substituted hydantoins for the treatment of cancer

Details for Australian Patent Application No. 2005284293 (hide)

Owner F. Hoffmann-La Roche AG

Inventors Moliterni, John Anthony; Kong, Norman; Huby, Nicholas John Silvester; McDermott, Lee Apostle; Zhang, Zhuming; Goodnow, Robert Alan Jr.

Agent Davies Collison Cave

Pub. Number AU-B-2005284293

PCT Pub. Number WO2006/029862

Priority 60/610,655 17.09.04 US

Filing date 15 September 2005

Wipo publication date 23 March 2006

Acceptance publication date 6 October 2011

International Classifications

C07D 417/12 (2006.01) Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group

A61K 31/427 (2006.01) - not condensed and containing further heterocyclic rings

A61P 35/00 (2006.01) Antineoplastic agents

C07D 417/14 (2006.01) Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group

Event Publications

19 April 2007 PCT application entered the National Phase

  PCT publication WO2006/029862 Priority application(s): WO2006/029862

6 October 2011 Application Accepted

  Published as AU-B-2005284293

2 February 2012 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2005284294-Thiazolinone 2-substituted quinolines

2005284292-Thiazolinone 4-monosubstituted quinolines